keyword
MENU ▼
Read by QxMD icon Read
search

Perioperative chemotherapy

keyword
https://www.readbyqxmd.com/read/28637567/the-impact-of-early-recurrence-on-quality-of-life-after-cytoreduction-with-hipec
#1
Nathan M Hinkle, Vandana Botta, John P Sharpe, Paxton Dickson, Jeremiah Deneve, Gitonga Munene
Improved oncological outcomes after cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in highly selected patients have been well documented. The extensive nature of the procedure adversely affects quality of life (QoL). The aim of this study is to longitudinally evaluate QoL following CRS/HIPEC. This is a retrospective review of a prospectively maintained database of patients with peritoneal malignancies undergoing CRS/HIPEC. Clinicopathological data, oncologic outcomes, and QoL were analyzed preoperatively and postoperatively at 2 weeks, and 1, 3, 6, and 12 months...
June 1, 2017: American Surgeon
https://www.readbyqxmd.com/read/28633580/platinum-agents-and-mitomycin-c-specific-complications-in-cytoreductive-surgery-crs-and-hyperthermic-intraperitoneal-chemotherapy-hipec
#2
Grace Hwei Ching Tan, Nicholas B Shannon, Claramae Shulyn Chia, Khee Chee Soo, Melissa Ching Ching Teo
INTRODUCTION: Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) have been found to prolong survival in patients with peritoneal disease but is associated with significant morbidity. We evaluate the perioperative complications and the association with the chemotherapy agent used for HIPEC. METHODS: Retrospective analysis of a prospectively collected database of CRS-HIPEC cases between April 2001 and February 2016 was performed. Patients were stratified by the chemotherapy used, and perioperative complications were compared...
June 20, 2017: International Journal of Hyperthermia
https://www.readbyqxmd.com/read/28633191/-urothelial-cancer-update-on-systemic-treatment-options
#3
Günter Niegisch
Perioperative chemotherapy is likely to improve survival in both the neoadjuvant and the adjuvant setting. Therefore, it is an integral part of the modern treatment of patients with muscle-invasive urothelial bladder cancer. All patients who are suitable for cisplatin-based chemotherapy should be involved in a corresponding concept.Cisplatin-based combinations are standard regimens in the perioperative and palliative systemic treatment of urothelial cancer. Carboplatin is only an inferior substitute for "unfit" patients in the palliative treatment situation...
June 20, 2017: Aktuelle Urologie
https://www.readbyqxmd.com/read/28628712/hyperthermic-intraperitoneal-chemoperfusion-as-a-component-of-multimodality-therapy-for-ovarian-and-primary-peritoneal-cancer
#4
Deepa Magge, Lekshmi Ramalingam, Yongli Shuai, Robert P Edwards, James F Pingpank, Steven S Ahrendt, Matthew P Holtzman, Herbert J Zeh, David L Bartlett, Haroon A Choudry
BACKGROUND AND OBJECTIVES: The role of hyperthermic intraperitoneal chemoperfusion (HIPEC) in the multimodality treatment of ovarian peritoneal metastases (OPM) and primary peritoneal cancer (PPC) remains controversial. We hypothesized that cytoreductive surgery (CRS) and HIPEC would provide meaningful survival benefit without excessive morbidity. METHODS: We reviewed clinicopathologic and perioperative data following 96 CRS-HIPEC procedures for primary or recurrent OPM and PPC...
June 19, 2017: Journal of Surgical Oncology
https://www.readbyqxmd.com/read/28625619/intra-thoracic-chemo-hyperthermia-for-pleural-recurrence-of-thymoma
#5
Jean Michel Maury, Nicolas Girard, Mayeul Tabutin, Renaud Grima, Lara Chalabreysse, Isabelle Pavlakovic, Annie Sayag-Beaujard, Caroline Leroux, Pierre-Jean Souquet, Olivier Glehen, François Tronc
BACKGROUND: Pleural recurrences are a hallmark of thymomas, and represent a challenge for multidisciplinary management. The purpose of this study was to assess the feasibility and the results in terms of morbidity, mortality and survival rates, of Intra-Thoracic Chemo-Hyperthermia (ITCH) for the treatment of pleural recurrences of thymomas. METHODS: Retrospective analysis of 19 consecutives patients between 1997 and 2015 treated by surgical cytoreduction (pleurectomy) followed by ITCH with 25mg/m(2) of mitomycin, and 50mg/m(2) of Cisplatin...
June 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/28624046/failure-to-rescue-following-cytoreductive-surgery-and-hyperthermic-intraperitoneal-chemotherapy
#6
Kevin Y Li, Ali A Mokdad, Rebecca M Minter, John C Mansour, Michael A Choti, Mathew M Augustine, Patricio M Polanco
BACKGROUND: Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) can significantly improve the survival in selected patients with peritoneal carcinomatosis. This study aims to identify perioperative patient characteristics predictive of failure to rescue (FTR), mortality following postoperative complications from CRS/HIPEC. METHODS: Patients suffering a complication following CRS/HIPEC between 2005 and 2013 were identified in the American College of Surgeons National Surgical Quality Improvement Program data set...
June 15, 2017: Journal of Surgical Research
https://www.readbyqxmd.com/read/28617714/perioperative-chemotherapy-with-and-without-high-dose-methotrexate-in-adult-osteosarcoma
#7
Marcelo Vailati Negrão, Lucila S da Silva Rocha, Daniel da Motta Girardi, Olavo Feher
Treatment of adult osteosarcoma (AOS) includes perioperative chemotherapy and surgery. Standard chemotherapy consists of cisplatin (CP) and doxorubicin (DOX). Although considered the standard of care for pediatric patients, high-dose methotrexate (HDM) remains controversial in adults. We aimed to evaluate the role of HDM in AOS treated with curative intent. This study included patients with AOS who received perioperative chemotherapy with DOX and CP (group 1; N=16) and DOX, CP, and HDM (group 2; N=10). The primary endpoint was grade 3 or superior toxicities...
June 14, 2017: Anti-cancer Drugs
https://www.readbyqxmd.com/read/28616608/gastric-cancer-treatment-in-the-world-germany
#8
REVIEW
Seung-Hun Chon, Felix Berlth, Patrick Sven Plum, Till Herbold, Hakan Alakus, Robert Kleinert, Stefan Paul Moenig, Christiane Josephine Bruns, Arnulf Heinrich Hoelscher, Hans-Joachim Meyer
Epidemiologically, around 15,500 persons per year contract gastric cancer with continuously decreasing incidence and a 5-year survival rate of only 30% to 35%. Contrary to the Asian countries, there are no prevention programs for gastric cancer in Germany, which leads to the disease frequently being diagnosed in locally advanced stages and predominantly being treated with multimodal therapy concepts. Complete (R0) resection is the therapy of choice for resectable gastric cancer. Special forms of gastric cancer that are limited to the mucosa can be endoscopically resected with a curative intent...
2017: Translational Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/28612013/oligometastatic-disease-in-colorectal-cancer-how-to-proceed
#9
REVIEW
Felix Aigner, Johann Pratschke, Moritz Schmelzle
BACKGROUND: Oligometastatic disease in colorectal cancer may affect the liver, lung, and peritoneum. This review mainly focuses on colorectal liver metastases (CRLM) and highlights recommendations and therapeutic strategies drawn from the current literature and consensus conferences. The following data address a paradigm shift in surgical approaches to CRLM, pushing the limits of multimodal treatment concepts. METHODS: A systematic review of the relevant literature on multimodal treatment strategies for synchronous and metachronous CRLM is presented...
March 2017: Visceral Medicine
https://www.readbyqxmd.com/read/28606725/do-packed-red-blood-cell-transfusions-really-worsen-oncologic-outcomes-in-colon-cancer
#10
Ramzi Amri, Anne M Dinaux, Lieve G J Leijssen, Hiroko Kunitake, Liliana G Bordeianou, David L Berger
BACKGROUND: Data from small retrospective studies have argued that perioperative packed red blood cell transfusions may increase the risk of developing metastatic recurrence in cancer patients. This study tests this assumption in a large cohort spanning a decade of operatively treated colon cancer patients. METHODS: All patients undergoing primary resection of a colon cancer at a tertiary care center between 2004-2014 (n = 1,423) were included in a retrospective review of a prospectively maintained data repository...
June 9, 2017: Surgery
https://www.readbyqxmd.com/read/28601189/has-survival-improved-following-resection-for-pancreatic-adenocarcinoma
#11
REVIEW
Kenneth Luberice, Darrell Downs, Benjamin Sadowitz, Sharona Ross, Alexander Rosemurgy
INTRODUCTION: This study was undertaken to determine if survival after resection of pancreatic adenocarcinoma has improved over the past two decades. METHODS: The SEER database was queried for patients who underwent pancreatectomy for pancreatic adenocarcinoma from 1992 to 2010. AJCC Stage and survival were determined for patients. Data were analyzed using Mantel-Cox test and linear regression. RESULTS: 15,604 patients underwent pancreatectomy from 1992 to 2010...
June 3, 2017: American Journal of Surgery
https://www.readbyqxmd.com/read/28600732/time-to-initiation-of-adjuvant-chemotherapy-in-pancreas-cancer-a-multi-institutional-experience
#12
Brent T Xia, Syed A Ahmad, Ali H Al Humaidi, Dennis J Hanseman, Cecilia G Ethun, Shishir K Maithel, David A Kooby, Ahmed Salem, Clifford S Cho, Sharon M Weber, Susan J Stocker, Mark S Talamonti, David J Bentrem, Daniel E Abbott
BACKGROUND: Despite randomized trials addressing adjuvant therapy (AT) for pancreas cancer, the ideal time to initiate therapy remains undefined. Retrospective analyses of the ESPAC-3 trial demonstrated that time to initiation of AT did not impact overall survival (OS). Given the absence of confirmatory data outside of a clinical trial, we sought to determine if AT timing in routine clinical practice is associated with OS differences. METHODS: Perioperative data of pancreatectomies for ductal adenocarcinoma from five institutions (2005-2015) were assessed...
June 9, 2017: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/28599137/management-of-advanced-ovarian-cancer-in-south-west-wales-a-comparison-between-primary-debulking-surgery-and-primary-chemotherapy-treatment-strategies-in-an-unselected-consecutive-patient-cohort
#13
F Drews, G Bertelli, K Lutchman-Singh
OBJECTIVES: This study represents the first reported outcomes for patients with advanced ovarian cancer (AOC) in South-West Wales undergoing treatment with primary debulking surgery or primary chemotherapy respectively. METHODS: This is a retrospective study of consecutive, unselected patients with advanced ovarian, fallopian tube or primary peritoneal cancer (FIGO III/IV) presenting to a regional cancer centre between October 2007 and October 2014. Patients were identified from Welsh Cancer Services records and relevant data was extracted from electronic National Health Service (NHS) databases...
June 6, 2017: Cancer Epidemiology
https://www.readbyqxmd.com/read/28591872/-the-role-of-immunooncology-in-the-treatment-of-urothelial-cancer
#14
Margitta Retz, Robert Tauber, Thomas Horn
Data published in November 2016 showed a significant survival benefit for the PD-1 antibody Pembrolizumab in the second-line treatment of metastatic urothelial cancer in comparison to standard chemotherapy. Other PD-1/PD-L1 antibodies are being tested in advanced clinical trials. This class of substances will become standard of care from the time of their approval which is expected for 2017 and will replace vinflunine, which is currently recommended in the German guideline. PD-1/PD-L1 directed substances are also being tested as a first line treatment of metastatic urothelial carcinoma...
June 7, 2017: Aktuelle Urologie
https://www.readbyqxmd.com/read/28586509/association-between-neoadjuvant-chemoradiation-and-survival-for-patients-with-locally-advanced-rectal-cancer
#15
Zhifei Sun, Mohamed A Adam, Jina Kim, Megan C Turner, Deborah A Fisher, Kingshuk Roy Choudhury, Brian G Czito, John Migaly, Christopher R Mantyh
AIM: To examine the overall survival differences of neoadjuvant therapy modalities: no therapy, chemotherapy alone, radiation alone, and chemoradiation in a large cohort of patients with locally advanced rectal cancer. METHOD: Adults with clinical stage II and III rectal adenocarcinoma were selected from the National Cancer Database and grouped by type of neoadjuvant therapies received: no therapy, chemotherapy only, radiotherapy only, or chemoradiation. Multivariable regression methods were used to compare adjusted differences in perioperative outcomes and overall survival...
June 6, 2017: Colorectal Disease: the Official Journal of the Association of Coloproctology of Great Britain and Ireland
https://www.readbyqxmd.com/read/28585317/modified-posterior-pelvic-exenteration-for-advanced-ovarian-malignancies-a-single-institution-study-of-35-cases
#16
Lubos Minar, Michal Felsinger, Ivo Rovny, Filip Zlamal, Julie Bienertova-Vasku, Eva Jandakova
INTRODUCTION: This study aimed to investigate the possible benefits of a complete cytoreduction in patients with advanced ovarian cancer and concomitant rectal invasion. Furthermore, we evaluated the morbidity associated with radical surgery. MATERIAL AND METHODS: A retrospective analysis examined 35 cases that underwent radical surgery in the form of modified posterior pelvic exenteration (MPPE). Descriptive statistics, Kaplan-Meier survival curves and Log-Rank test were used for statistical estimations...
June 6, 2017: Acta Obstetricia et Gynecologica Scandinavica
https://www.readbyqxmd.com/read/28579283/optimizing-management-of-upper-tract-urothelial-carcinoma
#17
REVIEW
Matthew T Campbell, Amishi Y Shah, Surena F Matin, Arlene O Siefker-Radtke
Upper tract urothelial cancer (UTUC) is a rare cancer of the urothelium, comprising only a fraction of cases as compared to urothelial tumors of the bladder. As a result, systemic treatment approaches in bladder cancer are often applied to patients with UTUC. Given the anatomical location of these tumors, the age, the comorbid conditions of these patients with UTUC, and the need for radical nephroureterectomy for treatment, most patients have substantial impairment of renal reserve. There is growing evidence for the benefit of perioperative chemotherapy in this disease...
June 1, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/28578652/icorg-10-14-neoadjuvant-trial-in-adenocarcinoma-of-the-oesophagus-and-oesophagogastric-junction-international-study-neo-aegis
#18
J V Reynolds, S R Preston, B O'Neill, L Baeksgaard, S M Griffin, C Mariette, S Cuffe, M Cunningham, T Crosby, I Parker, K Hofland, G Hanna, L B Svendsen, C L Donohoe, C Muldoon, D O'Toole, C Johnson, N Ravi, G Jones, A K Corkhill, M Illsley, J Mellor, K Lee, M Dib, V Marchesin, M Cunnane, K Scott, P Lawner, S Warren, S O'Reilly, G O'Dowd, G Leonard, B Hennessy, R Mc Dermott
BACKGROUND: Neoadjuvant therapy is increasingly the standard of care in the management of locally advanced adenocarcinoma of the oesophagus and junction (AEG). In randomised controlled trials (RCTs), the MAGIC regimen of pre- and postoperative chemotherapy, and the CROSS regimen of preoperative chemotherapy combined with radiation, were superior to surgery only in RCTs that included AEG but were not powered on this cohort. No completed RCT has directly compared neoadjuvant or perioperative chemotherapy and neoadjuvant chemoradiation...
June 3, 2017: BMC Cancer
https://www.readbyqxmd.com/read/28578357/is-survival-after-radical-cystectomy-for-bladder-cancer-in-saudi-patients-different-from-that-of-western-patients
#19
Alaa Mokhtar, Mohamed Matar Al, Waleed Mohamad Al, Khalid Al Othman, Said A Kattan, Mohammed Faihan Al
BACKGROUND: Although radical cystectomy (RC) is considered the gold standard treatment of muscle invasive bladder cancer, nearly half of patients develop metastases and ultimately die within 2 years. OBJECTIVE: To assess survival, evaluate different prognostic factors that may affect disease-free survival (DFS) in Saudi patients after RC for carcinoma of the bladder and to compare our results with those of Western countries. DESIGN: Retrospective chart review...
May 2017: Annals of Saudi Medicine
https://www.readbyqxmd.com/read/28561674/gastric-cancer-in-southern-europe-high-risk-disease
#20
Ramon Andrade De Mello
Gastric cancer is an aggressive disease. Several risk factors are involved in gastric cancer pathogenesis, likely Helicobacter pylori (H. pylori) infection, genetic factors in hereditary syndromes, lifestyle, and diet. However, well-implemented screening strategies are lacking in most countries, including those in Southern Europe. Nevertheless, gastric cancer outcomes are better in some Southern European countries than in others, likely because of the incidence and distribution of different histologic types...
2017: American Society of Clinical Oncology Educational Book
keyword
keyword
32529
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"